Abstract
The primary endpoint of 8-week progression-free rate was met with this combination.
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.
Skip Nav Destination
Article navigation
1 July 2022
Research Watch|
July 06 2022
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer
Cancer Discov (2022) 12 (7): OF20.
RSS Feeds